Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory Alignment Of UK With EU Post-Brexit Seen As Critical

Executive Summary

Retain high-quality regulatory capability and the innovative leadership of the UK medicines agency, align with the EU and don’t build a stand-alone regulatory system. Those are some of the recommendations in the new and wide-ranging industry-led Life Sciences Industrial Strategy relating to the future, post-Brexit regulation of medicines in the UK.

You may also be interested in...



Merck's UK Proposal: What's Attracting the US Giant To London For Innovation?

Merck & Co. will build a new innovation hub in London – an act described by the UK government as a major strategic investment – despite widespread Brexit ambiguity and a potentially unstable economic situation ahead for the soon-to-be ex-EU nation.

Yet Another UK Call For Views On What Brexit Means For Pharma, Regulation & Health

Another inquiry investigation into the consequences of Brexit in the life sciences area has been launched, this time by the UK House of Commons health committee. Stakeholders are asked to comment on issues like the impact on the regulation of medicines and medical devices, how to ensure continued access to medicines, and whether transitional arrangements will be needed.

UK Life Science Strategy Urges Adoption Of Accelerated Access Review, As Govt Prepares Response

A set of proposals in the recently published Life Sciences Industrial Strategy, aimed at improving the way new products are identified and made available under the NHS, reiterates ideas contained in the 2016 Accelerated Access Review. The government says it will respond to the review shortly.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel